Phase I Dose Escalation Trial of the First-in-Class TNFR2 Agonist Monoclonal Antibody, HFB200301, in Monotherapy and in Combination with Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in adult Patients with Advanced Solid Tumors

Phase I Dose Escalation Trial of the First-in-Class TNFR2 Agonist Monoclonal Antibody, HFB200301, in Monotherapy and in Combination with Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in adult Patients with Advanced Solid Tumors